Healthcare PharmaceuticalsEntresto
Owned by Novartis
Prescription cardiovascular medication combining sacubitril and valsartan for treating heart failure, developed and marketed by Novartis. Faced generic competition after July 2025 patent expiry following $7.7 billion in 2025 sales.
cardiovascularheart-failureprescription